Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere-Enoxaparin (ENOXA) Study in advanced NSCLC
2008-005433-30Phase 3Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of enoxaparin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Medizinische Hochschule Hannover. Primary endpoint: progression-free survival. Started Jan 2009; status: completed.
02
Drugs
enoxaparin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-005433-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005433-30.